CLINICAL CASE OF TREATMENT OF INVASIVE UROTHELIAL CANCER OF THE UPPER URINARY TRACT. PROBLEMS OF COMBINED TREATMENT

This article presents a clinical observation of the treatment of recurrent invasive urothelial cancer of the upper urinary tract using surgical and chemotherapy treatments. During the treatment, surgical treatment and 2 chemotherapy lines were performed. The patient was under strict dynamic control, during which diagnostic procedures were carried out, which allowed time to identify the progression of the underlying disease and prescribe timely treatment of identifi ed relapses.

At the first stage, the patient underwent surgical radical treatment to remove the primary tumor focus localized in the lower third of the right ureter. At the control examination a local relapse was revealed. The 1st line of chemotherapy was prescribed and performed, against which the full effect of the treatment was noted. But in the future, the progression of the disease was revealed, which required the 2nd line of chemotherapy with preliminary surgical removal of a local relapse.

1. The state of cancer care in Russia in 2015. Edited by Kaprin AD, Starinskii VV, Petrova GV. Мoscow, 2016, 250 p. Available at: http://www.oncology.ru/service/statistics/condition/ (In Russian).

2. Kaprin AD, Galkin VN, Zhavoronkov LP, Ivanov VK, Ivanov SA, Romanko YuS. Synthesis of basic and applied research is the basis of obtaining high-quality fi ndings and translating them into clinical practice. Radiation and Risk. 2017;26 (2):26–40. DOI: 10.21870/0131–3878–2017–26–2-26–40 (In Russian).

3. Siegel RL, Miller KD, Jemal A. Cancer statistics 2015. CA Cancer J Clin. 2015 Jan-Feb;65 (1):5–29. DOI: 10.3322/caac.21254.

4. Matveev VB, Volkova MI, Afonin SV, Romanov VA. Upper urinary tract tumors: 23-year experience of a clinic. Cancer Urology. 2011;2;39–45. (In Russian).

5. Cosentino M, Palou J, Gaya JM, Breda A, Rodriguez-Faba O, Villavicencio-Mavrich H. Upper urinary tract urothelial cell carcinoma: location as a predictive factor for concomitant bladder carcinoma. World J Urol. 2013 Feb;31 (1):141–5. DOI: 10.1007/s00345–012–0877–2.

6. Crivelli JJ, Xylinas E, Kluth LA, Rieken M, Rink M, Shariat SF. Effect of smoking on outcomes of urothelial carcinoma: a systematic review of the literature. Eur Urol. 2014 Apr;65 (4):742–54. DOI: 10.1016/j.eururo.2013.06.010

7. Grollman AP, Shibutani S, Moriya M, Miller F, Wu L, Moll U, et al. Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc Natl Acad Sci U S A. 2007 Jul 17;104 (29):12129–34. DOI: 10.1073/pnas.0701248104

8. Colin P, Koenig P, Ouzzane A, Berthon N, Villers A, Biserte J, Rouprêt M. Environmental factors involved in carcinogenesis of urothelial cell carcinomas of the upper urinary tract. BJU Int. 2009 Nov;104 (10):1436–40. DOI: 10.1111/j.1464–410X.2009.08838.x.

9. Brierley JD, et al. TNM classifi cation of malignant tumors. UICC International Union Against Cancer. 8th edn. Oxford, 2017.

10. Moch H, et al. WHO Classifi cation of Tumours of the Urinary System and Male Genital Organs. 4th ed. Lyon, France, 2016.

11. Volkova MI, Matveev VB, Medvedev SV, Nosov DA, Figurin KM, Khmelevskii EV, Chernyaev VA. Klinicheskie rekomendatsii po diagnostike i lecheniyu bol’nykh rakom mochevogo puzyrya [Diagnosis and treatment of bladder cancer: clinical practice guidelines]. Moscow, 2014. (In Russian).

12. Rouprêt M, Babjuk M, Burger M, Compérat E, Cowan N, Gontero P, et al. Upper Urinary Tract Urothelial Cell Carcinoma. EAU Guidelines. 2017.

13. Seisen T, Granger B, Colin P, Léon P, Utard G, Renard-Penna R, et al. A Systematic Review and Meta-analysis of Clinicopathologic Factors Linked to Intravesical Recurrence After Radical Nephroureterectomy to Treat Upper Tract Urothelial Carcinoma. Eur Urol. 2015 Jun;67 (6):1122–1133. DOI: 10.1016/j.eururo.2014.11.035

14. Sakano S, Matsuyama H, Kamiryo Y, Hayashida S, Yamamoto N, Kaneda Y, et al. Impact of variant histology on disease aggressiveness and outcome after nephroureterectomy in Japanese patients with upper tract urothelial carcinoma. Int J Clin Oncol. 2015 Apr;20 (2):362–8. DOI: 10.1007/s10147–014–0721–3.

15. Li WM, Shen JT, Li CC, Ke HL, Wei YC, Wu WJ, et al. Oncologic outcomes following three diff erent approaches to the distal ureter and bladder cuff in nephroureterectomy for primary upper urinary tract urothelial carcinoma. Eur Urol. 2010 Jun;57 (6):963–9. DOI: 10.1016/j.eururo.2009.12.032.

16. Margulis V, Shariat SF, Matin SF, Kamat AM, Zigeuner R, Kikuchi E, et al. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer. 2009 Mar 15;115 (6):1224–33. DOI: 10.1002/cncr.24135

17. Park J, Habuchi T, Arai Y, Ohyama C, Inoue T, Hatakeyama S, et al. Reassessment of prognostic heterogeneity of pT3 renal pelvic urothelial carcinoma: analysis in terms of proposed pT3 subclassification systems. J Urol. 2014 Oct;192 (4):1064–71. DOI: 10.1016/j.juro.2014.04.001

18. Fang D, Li XS, Xiong GY, Yao L, He ZS, Zhou LQ. Prophylactic intravesical chemotherapy to prevent bladder tumors after nephroureterectomy for primary upper urinary tract urothelial carcinomas: a systematic review and meta-analysis. Urol Int. 2013;91 (3):291–6. DOI: 10.1159/000350508

19. Vassilakopoulou M, de la Motte Rouge T, Colin P, Ouzzane A, Khayat D, Dimopoulos MA, et al. Outcomes after adjuvant chemotherapy in the treatment of high-risk urothelial carcinoma of the upper urinary tract (UUT-UC): results from a large multi-center collaborative study. Cancer. 2011 Dec 15;117 (24):5500–8. DOI: 10.1002/cncr.26172

20. Leow JJ, Martin-Doyle W, Fay AP, Choueiri TK, Chang SL, Bellmunt J. A Systematic Review and Meta-analysis of Adjuvant and Neoadjuvant Chemotherapy for Upper Tract Urothelial Carcinoma. Eur Urol. 2014 Sep;66 (3):529–41. DOI: 10.1016/j.eururo.2014.03.003.

21. Galsky MD, Krege S, Lin CC, Hahn N, Ecke TH, Moshier E, et al. Cisplatin-based combination chemotherapy in septuagenarians with metastatic urothelial cancer. Urol Oncol. 2014 Jan;32 (1):30. e15–21. DOI: 10.1016/j.urolonc.2012.11.001